---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Expected outcomes of therapy"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Expected outcomes of therapy. Topics: Himalayas-1 objective and endpoints, Company-stated therapeutic goal, Company benchmark for approved post-ARPI therapies, Control-arm outcomes with an alternative ARPI or docetaxel after a first ARPI, and 1 further topic. 5 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Himalayas-1 objective and endpoints

> “Himalayas-1 is evaluating whether rinzimetostat plus darolutamide improves outcomes compared with physician’s choice of an ARPI or docetaxel in patients with mCRPC previously treated with abiraterone”
> “The primary endpoint is radiographic progression-free survival (rPFS), with overall survival (OS) as the key secondary endpoint”
> “OS will be formally tested only if the primary rPFS analysis is statistically significant”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.2.2.7-2"></a>

### Company-stated therapeutic goal

> “Combining rinzimetostat with darolutamide may limit tumor cell adaptation and prolong clinical benefit from continued androgen receptor pathway inhibition”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “the initiation of our Himalayas-1 Phase 3 trial represents an important milestone toward establishing rinzimetostat as a potentially practice-changing therapy for patients”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.2.2.7-3"></a>

### Company benchmark for approved post-ARPI therapies

> “For reference, the 5-month landmark rPFS for these approved therapies ranges from approximately 60% to 75%.”

Source: [ORIC Pharmaceuticals first quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates/)

> “PRC2 inhibitors in combination with an AR inhibitor have demonstrated much longer rPFS (key regulatory primary endpoint) than what has been reported with other approved and emerging therapies”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.2.2.7-4"></a>

### Control-arm outcomes with an alternative ARPI or docetaxel after a first ARPI

> “In the control arm of the contemporary PSMAfore trial, the ARPI-switch showed an rPFS of 5.59 months (4.21–5.95)”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “employed physician’s choice of docetaxel or second-generation ARPI as the control, and reported an imaging-based PFS of 6.4 months in the control group”

Source: [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)

<a id="topic-2.2.2.7-5"></a>

### US real-world outcomes after a prior androgen receptor pathway inhibitor

> “In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.”

Source: [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/)

> “Median time from start of 1 L to next LOT or end of follow-up was 13.7 months, 10.9 months from 2 L start, and 8.9 months from 3 L start.”
> “Median survival was 25.6 months after mCRPC and 23.4 months following treatment initiation.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
